Cargando…

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function. Thus, tofacitinib therapy may result in suppression of multiple elements...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Ahadieh, Sima, French, Jonathan, Geier, Jamie, Krishnaswami, Sriram, Menon, Sujatha, Checchio, Tina, Tensfeldt, Thomas G., Hoffman, Elaine, Riese, Richard, Boy, Mary, Gómez-Reino, Juan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704538/ https://www.ncbi.nlm.nih.gov/pubmed/26669566 http://dx.doi.org/10.1186/s13075-015-0880-2

Ejemplares similares

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
por: Strand, Vibeke, et al.
Publicado: (2017)

Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers
por: Menon, Sujatha, et al.
Publicado: (2016)

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
por: Isaacs, John D, et al.
Publicado: (2014)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib
por: Curtis, Jeffrey R., et al.
Publicado: (2016)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis
por: Checchio, T, et al.
Publicado: (2017)

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
por: Clowse, Megan E. B., et al.
Publicado: (2016)

Model‐Based Comparison of Dose‐Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients
por: Suzuki, Misaki, et al.
Publicado: (2019)

Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
por: Scheinberg, Morton, et al.
Publicado: (2017)

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
por: Miyoshi, So, et al.
Publicado: (2019)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
por: Kremer, Joel M., et al.
Publicado: (2021)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs
Publicado: (2017)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
por: Nash, Peter, et al.
Publicado: (2018)

Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2020)

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
por: Winthrop, K L, et al.
Publicado: (2016)

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
por: Fleischmann, Roy, et al.
Publicado: (2016)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
por: Ozen, Gulsen, et al.
Publicado: (2019)

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
por: Song, Gwan Gyu, et al.
Publicado: (2014)

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
por: Curtis, Jeffrey R, et al.
Publicado: (2023)

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
por: Cohen, Stanley B, et al.
Publicado: (2017)

Use of Tofacitinib in the Context of COVID‐19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
por: Mortezavi, Mahta, et al.
Publicado: (2021)

Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID‐19 Clinical Trials
por: Hughes, Jim H., et al.
Publicado: (2020)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
por: Riek, Myriam, et al.
Publicado: (2023)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
por: Strand, Vibeke, et al.
Publicado: (2021)

A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping
por: Pouls, Bart PH, et al.
Publicado: (2022)

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2014)

Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial
por: Li, Zhanguo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_apuvt2c08pbds4dn3ss88fuor4